Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-BTC01: T-DXd and Rilvegostomig in Biliary Tract Cancer
NCT06467357Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Primary completion
- Jun 2028
- Countries
- 27
01
Overview
Phase 3, randomised trial in biliary tract cancer (BTC) comparing Trastuzumab deruxtecan + rilvegostomig, Trastuzumab deruxtecan and Standard of Care (3 arms). Primary endpoints: Safety and Tolerability of T-DXd with rilvegostomig and Overall Survival up to 50 months. Started Aug 2024; status: recruiting.
02
Drugs
trastuzumab deruxtecanrilvegostomig
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06467357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06467357.